For instance, over 95% of pancreatic cancers carry KRASG12D mutations, and 70% carry TP53 mutations.[62] In our study, we tested the in vitro toxicity and internalization of our systems on a panel of three different pancreatic cancer cell lines: BxPC‐3 (wt‐KRAS, TP53Y220C), MIA‐PaCa‐2 (KRASG12C, TP53R248W), and PANC‐1 (KRASG12D, TP53R273H). Here, KRAS is linked to pancreatic neoplasm.